TheraRadar
Data updated: May 26, 2026

LOFEXIDINE HYDROCHLORIDE

Trial Activity: Declining
CNS Approved 2024-08-20

Lofexidine hydrochloride helps adults manage the physical symptoms that occur when they suddenly stop taking opioids. It is used to make the process of opioid discontinuation more manageable for patients. This medication provides support during the transition period to help individuals successfully stop their opioid use.

Source: FDA Label • MSN

How LOFEXIDINE HYDROCHLORIDE Works

This drug works by binding to alpha-2 adrenergic receptors on neurons in the central nervous system. This interaction reduces the release of norepinephrine and lowers sympathetic tone. By decreasing these signals, the medication helps mitigate the physiological effects of opioid withdrawal.

Source: FDA Label

Development Insights

USWM, LLC (dba US WorldMeds) conducting 3 trials (100%)
2 indications explored (Focused)
normal healthy volunteers will be treated with lofexidine to understand the absolute bioavailability and mass balance recovery of the product (2 trials)
normal healthy volunteers (1 trials)
3
Indications
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2024-08-20
Routes
ORAL
Dosage Forms
TABLET

LOFEXIDINE HYDROCHLORIDE Approval History

2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2024 to 2025
Oct 2025 ORIGINAL
Update
Feb 2025 ORIGINAL
Update
Aug 2024 ORIGINAL
Update

What LOFEXIDINE HYDROCHLORIDE Treats

1 indications

LOFEXIDINE HYDROCHLORIDE is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Opioid Withdrawal
Source: FDA Label

LOFEXIDINE HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

MoA expansion candidates

3

Same target(s), different indications — where else is this mechanism being explored?

Unlock 1 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LOFEXIDINE HYDROCHLORIDE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

LUCEMYRA
LOFEXIDINE HYDROCHLORIDE
1 shared
BIOCORRX PHARMS
Shared indications:
Opioid Withdrawal
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT01629446 USWM-LX1-1003-1 1R01DA030916-01 Ph 1 completed Lofexidine Mass Balance in Volunteers
NCT01310296 USWM-LX1-1003/ 02749MZ Ph 1 completed Lofexidine ADME & Mass Balance in Volunteers
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LOFEXIDINE HYDROCHLORIDE FDA Label Details

Indications & Usage

LOFEXIDINE HYDROCHLORIDE is indicated for the treatment of Opioid Withdrawal.

Looking for the branded version?

LUCEMYRA

Full clinical data, patents, trials, and competitive landscape for lofexidine hydrochloride.

See LUCEMYRA

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment